Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (Nasdaq: KURA) is a biopharmaceutical company focused on precision medicines for cancer, and its news flow reflects the evolution of this strategy. Company announcements highlight progress with KOMZIFTI (ziftomenib), an oral menin inhibitor approved in the United States for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.
News items for KURA commonly cover regulatory milestones, clinical data and commercial updates. Recent releases describe full FDA approval of KOMZIFTI, its addition to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a Category 2A recommended option for relapsed or refractory NPM1-mutated AML, and the start of U.S. commercial sales. Kura also reports on its collaboration with Kyowa Kirin, including milestone payments tied to clinical and commercial events.
Investors following KURA news can expect detailed coverage of clinical trial readouts from programs such as KOMET-001, KOMET-007 and KOMET-017, which evaluate ziftomenib across newly diagnosed and relapsed or refractory AML, often in combination with regimens like cytarabine/daunorubicin and venetoclax/azacitidine. Additional news addresses the company’s farnesyl transferase inhibitor programs, darlifarnib and tipifarnib, and their activity in solid tumors.
Kura’s press releases also include corporate updates such as financial results, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in scientific and investor conferences. For readers tracking KURA, this news page offers a centralized view of key developments in its precision oncology pipeline, regulatory interactions, collaborations and commercialization activities.
Kura Oncology reported its Q2 2022 financial results and highlighted significant advancements in its clinical programs. The company identified a recommended Phase 2 dose for ziftomenib, pending FDA review, and enrolled an additional 18 patients in the KOMET-001 trial targeting acute myeloid leukemia. They observed preliminary efficacy in the KURRENT-HN trial of tipifarnib with alpelisib. Kura holds $450 million in cash and equivalents, expected to fund operations through 2024.
Kura Oncology, a clinical-stage biopharmaceutical company focused on cancer treatments, will participate in the Wedbush PacGrow Healthcare Virtual Conference on August 9, 2022. CEO Troy Wilson will be on a panel titled “Bullseye - Targeted Oncology – In with the New,” scheduled for 10:20 AM ET. A live audio webcast will be available on Kura's website, with a replay to follow. The company is advancing its pipeline, including Ziftomenib in a Phase 1b trial for relapsed AML, while Tipifarnib is in registration trials for HRAS mutant HNSCC.
Kura Oncology (Nasdaq: KURA) will announce its second quarter 2022 financial results on August 3, 2022, after U.S. market close. Following this, management will host a webcast at 4:30 p.m. ET to discuss the results and provide a corporate update. Key programs include Ziftomenib in a Phase 1b trial for AML, and Tipifarnib, which has received Breakthrough Therapy Designation for HRAS mutant HNSCC. The company is also advancing multiple trials to provide precision treatments for various cancer types.
Kura Oncology, a clinical-stage biopharmaceutical company, announced that Troy Wilson, Ph.D., J.D., its CEO, will participate in three investor conferences:
- Virtual fireside chat at Cowen’s 3rd Annual Oncology Innovation Summit on June 2, 2022.
- Fireside chat at the Jefferies Healthcare Conference in New York on June 8, 2022.
- Fireside chat at the JMP Securities Life Sciences Conference in New York on June 16, 2022.
Audio webcasts will be accessible on Kura's website.
Kura Oncology, Inc. (Nasdaq: KURA) has completed enrollment for the Phase 1b expansion cohorts of ziftomenib, with topline data expected in Q3 2022. The company anticipates initial patient dosing in the HRAS cohort of the KURRENT-HN trial and the KURRENT-LUNG trial by Q3 2022. As of March 31, 2022, Kura reported cash and equivalents totaling $480 million, projected to sustain operations through 2024. The company experienced a net loss of $32.5 million for Q1 2022, with R&D expenses rising to $20.9 million. Management will hold a conference call today to discuss the financial results and updates.
Kura Oncology (Nasdaq: KURA) announced that it will release its first quarter 2022 financial results on May 4, 2022, after market close. A conference call with management will take place at 4:30 p.m. ET to discuss the results and provide a corporate update. The call can be accessed via phone or streamed online. Kura Oncology focuses on precision cancer treatments and has multiple clinical trials underway, including Ziftomenib for relapsed AML and Tipifarnib for HRAS mutant HNSCC.
Kura Oncology (KURA) presented new preclinical data at the AACR Annual Meeting, showcasing the potential of its farnesyl transferase inhibitor (FTI), tipifarnib, to delay drug resistance to osimertinib in EGFR mutant non-small cell lung cancer (NSCLC). The data indicate that tipifarnib successfully clears drug-tolerant cells and prevents relapse to osimertinib for six months in preclinical models, with no observed toxicity. The company plans to start a Phase I trial of tipifarnib with osimertinib in third-quarter 2022 and submit an IND for next-gen FTI KO-2806 by year-end.
Kura Oncology, Inc. (Nasdaq: KURA) announced the acceptance of four abstracts for presentation at the AACR Annual Meeting in New Orleans, from April 8-13, 2022. The presentations will focus on the company’s farnesyl transferase inhibitor program, particularly tipifarnib, which aims to delay drug resistance in cancer treatment. The CEO, Troy Wilson, emphasized the importance of ongoing trials for non-small cell lung cancer and the advancement of KO-2806. Detailed presentations will be available on Kura’s website following the conference.
Kura Oncology, Inc. (Nasdaq: KURA) announced that CEO Troy Wilson will participate in two investor conferences in March 2022. He will join a panel on "Leukemias/MPN" at the Cowen 42nd Annual Health Care Conference on March 7 at 10:30 a.m. ET, followed by a fireside chat at the Barclays Global Healthcare Conference in Miami on March 15 at 11:15 a.m. ET. Audio webcasts of both events will be available on Kura's website, with replays archived post-event. Kura focuses on precision cancer medicines and has notable candidates like Ziftomenib and Tipifarnib in clinical trials.
Kura Oncology reported its financial results for Q4 and full year 2021, emphasizing advancements in its clinical programs, particularly in the KOMET-001 Phase 1b study of ziftomenib for acute myeloid leukemia (AML). The company has resumed patient enrollment and expects to complete it by Q2 2022, with top-line data anticipated by Q3 2022. Kura has $518 million in cash, providing operational stability into 2024. Significant data readouts are expected in the upcoming year, marking a pivotal phase for the company's drug development pipeline.
FAQ
What is the current stock price of Kura Oncology (KURA)?
What is the market cap of Kura Oncology (KURA)?
